Crinetics Pharmaceuticals
CRNX
71 hedge funds and large institutions have $475M invested in Crinetics Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 13 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
3.48% less ownership
Funds ownership: 95.74% → 92.26% (-3.5%)
10% less funds holding
Funds holding: 79 → 71 (-8)
13% less capital invested
Capital invested by funds: $546M → $475M (-$70.7M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.93M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.79M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.77M |
| 4 |
Goldman Sachs
New York
|
+$1.34M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$870K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15.1M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$3.07M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.98M |
| 4 |
Morgan Stanley
New York
|
-$2.65M |
| 5 |
Millennium Management
New York
|
-$1.98M |
CRNX Hedge Fund Activity: Q3 2020 in Review
71 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2020, worth a combined $475M — down 13% from $546M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CRNX and 5 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 22 added.
The largest buyer was Wellington Management Group, adding an estimated $1.93M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $15.1M sold.
- 71 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2020, down from 79 in Q2 2020.
- Funds reported $475M of Crinetics Pharmaceuticals stock for Q3 2020, down 13% quarter-over-quarter.
- 5 funds opened new Crinetics Pharmaceuticals positions in Q3 2020 and 13 closed out, a net change of -8 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2020 was Wellington Management Group, an estimated $1.93M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2020 was EcoR1 Capital, an estimated $15.1M sold.
Based on aggregated 13F filings for Q3 2020.